-+ 0.00%
-+ 0.00%
-+ 0.00%

Did Li Ning’s Fall Catch You Out? What Investors Missed

Simply Wall St·10/17/2026 13:31:19
語音播報

If you had decided on 1 January 2026 that Li Ning looked too contentious, with bulls talking up premium health trends and e-commerce while bears stressed China exposure and price wars, stepping aside might feel like a relief now. Investors who held Li Ning from the start of the year are down 25.1%, including dividends. Given what analysts had already published by then, which assumptions about margins, demand, or competition most merited extra scrutiny?

On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.

Li Ning has already moved. See which of 191 high quality undervalued stocks still trade below our estimates.

The Two Li Ning Stories Investors Had To Weigh

The shares cost HK$18.67 at the start, and Li Ning sat between two sharply different readings of what its future could look like.

On the optimistic side, the bullish Narrative put Fair Value at HK$33.58 and leaned on health trends and e-commerce. It assumed higher pricing power from premium and professional products, as well as a faster channel shift as online integration improved margins.

The bearish view carried a Fair Value of HK$12.06 and focused on China risk. It highlighted pressure from discounting, rising marketing and sponsorship expenses, and margin compression as key concerns.

SEHK:2331 Trailing 12-Month Earnings & Revenue History as at Oct 2026
SEHK:2331 Trailing 12-Month Earnings & Revenue History as at Oct 2026

What The Results Changed For The Li Ning Debate

The 2026 interim report gave Li Ning bulls fresh support. Revenue reached RMB15,235 million in H1 2026, up from RMB14,817 million a year earlier, and net income also rose. Net margin edged from 11.7% to 11.9%. The Stephen Curry partnership and product push fit the premium, performance story, while upfront sponsorship costs kept the cautious case alive. Overall, the evidence cut both ways.

The lesson is simple. When a thesis leans on premium pricing and brand upgrades, track gross and net margin alongside any big endorsement deals or technology launches. Then check if reported profitability moves in the same direction as the promise.

What Li Ning’s Price Drop Asks You To Believe

Li Ning now trades at HK$13.28, leaving holders down 25.1% from the start of the year. The selected bullish Narrative still places Fair Value above that level and centres on performance gear, technology platforms and the Stephen Curry partnership as the key swing factors.

For the fall to look like an opportunity rather than a warning, a buyer today would need to believe performance categories can carry higher margins while heavy marketing and Olympic spending remain manageable.

"Rising contribution from professional sports categories such as running and badminton, which already account for over half of Li Ning revenue, creates room for a further shift in product mix toward performance gear that can support higher average selling prices and help lift gross margin and earnings quality."

One Narrative disagrees with today's price. → See where this Narrative says Li Ning should trade

Looking Beyond Li Ning

Li Ning lives in a crowded arena. Your thesis might benefit from looking sideways, not just locally.

Sports brands competing for share still rely on one basic thing. They need buyers across income levels who keep choosing their gear.

One global rival has built its model around that breadth. It uses scale and pricing to keep products within reach for mass consumers.

That focus on wide affordability, plus a growing direct channel, aims at resilience when conditions feel tougher.

If Li Ning is your question stock, this broader operator could be a useful comparison point.

The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 16% above its price

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.